Gita Vaid, MD, is the Co-founder and Medical Director of the Center for Natural Intelligence, a multidisciplinary laboratory specializing in psychedelic psychotherapy innovation and clinical practice. As a board-certified psychiatrist and psychoanalyst, she was trained by the Multidisciplinary Association for Psychedelics Studies (MAPS) to practice ketamine-assisted psychotherapy. Gita is also the Director of Psychedelic Awareness at The Chopra Foundation and a lead instructor at The Ketamine Training Center.

Psychedelic-assisted psychotherapy is a powerful modality for healing trauma, deepening self-awareness, and fostering emotional transformation. Yet, it requires profound therapeutic relationships, boundaries, and integration. What does it take to facilitate psychological healing with psychedelic therapy?

Psychiatrist and psychoanalyst Gita Vaid takes a relational and process-oriented approach to psychedelic-assisted psychotherapy. Ketamine-assisted psychotherapy can reactivate emotional connection, surface suppressed trauma, and promote personal growth when guided by an attuned therapeutic relationship. Gita emphasizes the value of clinician self-development, stating that true transformation occurs when the therapist and patient engage in a co-healing process. She advises practitioners to trust the unfolding nature of psychedelic work, listen carefully to their clients’ inner narratives, and prioritize building safety and intimacy throughout treatment.

In this episode of Living Medicine, Dr. Sandy Newes interviews Gita Vaid, MD, Co-founder and Medical Director at the Center for Natural Intelligence, about the clinical and relational depth of psychedelic-assisted therapy. Gita discusses attachment repair, the shift from trauma identity to well-being, and how music and innovation can enhance the healing process.

Dr. Signi Goldman, MD, is a board-certified psychiatrist and the Co-founder and Medical Director of Living Medicine Institute, which offers psychedelic-assisted psychotherapy training programs. As a certified provider for psychedelic-assisted therapy and research, she has practiced in various clinical settings, including hospital systems and alternative treatment settings. Dr. Goldman also serves as a Psychiatrist and Psychotherapist for Concierge Medicine and Psychiatry’s Ketamine-Assisted Psychotherapy Program for Mental Health.

Dr. Sandra (Sandy) Newes, PhD, is a licensed psychiatrist and the Co-founder and Programming Director of Living Medicine Institute. With over 25 years of clinical experience as a psychedelic-assisted psychotherapist, she specializes in anxiety, chronic stress, trauma, and recovery. Dr. Newes has provided ketamine-assisted psychotherapy through Concierge Medicine and Psychiatry since 2019. She is also an educator and speaker offering workshops, events, and education on psychedelic-assisted psychotherapy and the intersection of nature connection, trauma, and mental health.

Many people struggling with trauma, anxiety, or emotional blocks have turned to alternative therapies for healing, but are these methods truly effective? With growing interest in psychedelics like ketamine and MDMA, questions remain about how these substances are used, who they help, and what actually happens during therapy. What does safe, effective psychedelic-assisted psychotherapy look like in practice?

Various medical and psychiatric professionals share their lived experiences and clinical insights into this emerging field. Veteran psychedelic researcher Bill Richards maintains that the psyche can heal itself when supported by empathy and presence during psychedelic-assisted psychotherapy sessions. Internal Family Systems creator Dr. Dick Schwartz believes each individual is composed of distinct parts with trauma impacting their individual functions. Emergency medicine provider Mel Herbert details therapeutic environments that promote psychedelic integration, while MDMA researcher Michael Mithoefer emphasizes the importance of preparation and post-session dialogue and reflection for long-term impact.

In this exclusive compilation episode of Living Medicine, Dr. Signi Goldman and Dr. Sandy Newes of Living Medicine Institute reflect on their most insightful interviews. Featuring conversations with Bill Richards, Dr. Dick Schwartz, Michael Mithoefer, and Mel Herbert, these guests delve into therapeutic safety, the role of integration after ketamine sessions, and promoting healing in psychedelic-assisted psychotherapy.

Jayne Gumpel, LCSW, is the Founder and Lead Facilitator of Relationship Resources, which offers psychedelic-assisted retreats. As a psychotherapist, trainer, and teacher, she has over 30 years of experience working with couples, individuals, and groups in private practice. Jayne is a certified trainer in Psychedelic Integration Psychotherapy, a member of the Woodstock Therapy Center’s Ketamine-Assisted Psychotherapy (KAP) team, and has completed MDMA-assisted psychotherapy training through the Multidisciplinary Association for Psychedelic Studies (MAPS).

Couples may encounter challenges when trying to resolve persistent issues around communication, trust, or emotional pain. Traditional talk therapy sometimes falls short when couples try to break through entrenched narratives and create meaningful change. How can therapists help partners reach deeper understanding and healing in a safe, transformative way?

According to psychedelic-assisted psychotherapist and couples retreat facilitator Jayne Gumpel, ketamine can act as a portal to emotional clarity and reconnection. Having facilitated both individual and group ketamine sessions, Jayne emphasizes the importance of preparation, intention setting, and integration. This medicine quiets the brain’s default mode of thinking, helping clients detach from rigid meaning-making and approach difficult emotions with compassion. Jayne also integrates poetry into her clinical practice to help clients reframe their stories and deepen relational insight.

In this week’s episode of Living Medicine, Dr. Sandy Newes sits down with Jayne Gumpel, LCSW, Founder and Lead Facilitator of Relationship Resources, to discuss psychedelic-assisted couples therapy. Jayne shares her philosophy for cultivating joy, her innovative retreat approaches, and her perspective on consciousness.

Jim Hopper, PhD, is a Teaching Associate in Psychology at Harvard Medical School, where he co-directs a conference on psychedelic-assisted psychotherapy. With over 25 years of experience as a clinical psychologist, therapist, and independent forensic consultant, he focuses on the psychological and neurobiological effects of trauma, including sexual assault and child abuse, and their treatment. Jim has provided training and consultation to therapists, law enforcement, military personnel, and higher education administrators and has served as an expert witness in legal cases.

Many clinicians entering the field of psychedelic-assisted psychotherapy assume that the medicine alone drives healing, overlooking the critical role of the therapeutic relationship. Without a strong relational foundation, clients can experience retraumatization, disempowerment, or even harm during these vulnerable states. How can practitioners create safe, empowering, and effective therapeutic environments during psychedelic-assisted psychotherapy?

As a clinical psychologist specializing in trauma and psychedelic-assisted psychotherapy, Jim Hopper advises clinicians to combine empowerment, connection, and attunement during psychedelic therapy sessions. He advocates for trauma-informed care that supports client autonomy and competence while maintaining a genuine relational connection. Preparation, integration, and an awareness of relational dynamics like transference and countertransference are essential components of the psychedelic therapy process. By maintaining faith in the client’s inner healing wisdom, therapists can help clients feel safe, empowered, and supported throughout their healing journeys.

In this week’s episode of Living Medicine, Dr. Sandy Newes interviews Jim Hopper, PhD, Teaching Associate at Harvard Medical School, about creating safe and relational psychedelic-assisted psychotherapy sessions. Jim talks about balancing autonomy and competence, avoiding therapist overreach, and the risks of replicating trauma dynamics in therapy.

Rick Doblin, PhD, is the Founder and President of MAPS (Multidisciplinary Association for Psychedelic Studies), a nonprofit organization advancing research into the therapeutic potential of psychedelics. He studied under Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. Rick aims to develop legal contexts for the beneficial uses of psychedelics and marijuana.

The path to healing trauma and advancing mental health care through psychedelic therapies is often blocked by regulatory barriers, cultural stigma, and skepticism. While MDMA-assisted psychotherapy shows immense promise, therapists wonder how these treatments can be made widely accessible and trusted, especially across different cultures, age groups, and medical systems. What does it take to shift public perception and institutional acceptance?

Psychedelic researcher and therapy pioneer Rick Doblin combines rigorous clinical research, international therapist training, and grassroots cultural change to reduce the stigma surrounding psychedelic therapies. He has initiated humanitarian projects in high-trauma, low-resource regions like Ukraine and Rwanda and facilitated the FDA approval process through pilot studies and collaborative research. Rick emphasizes the importance of therapist training — including firsthand MDMA experience — and encourages public storytelling to destigmatize psychedelics and build broader support.

In today’s episode of Living Medicine, Dr. Sandy Newes welcomes Rick Doblin, PhD, Founder and President of MAPS, to discuss his pioneering research into MDMA and other psychedelic-assisted psychotherapies. Rick talks about group and family psychedelic therapy models, the relationship between mysticism and therapeutic outcomes during psychedelic sessions, and how to support natural emotions during vulnerable states.

Dr. Erika Czerwinski, PsyD, is the Founder, Director, and Facilitator of Eleos, which integrates ketamine-assisted psychotherapy and nature-based mindfulness to facilitate self-discovery. With over 20 years of clinical experience working with individuals, couples, and groups, Dr. Czerwinski holds certifications in psychedelic-assisted therapies from MAPS, the Integrative Psychiatric Institute, and the Living Medicine Institute. Since 2019, she has facilitated ketamine-assisted psychotherapy for physicians, young adults, and those healing from trauma.

As the psychotherapy space enters a psychedelic renaissance, navigating the complex relational dynamics that emerge in altered states remains a top concern. How can therapists maintain ethical boundaries while being authentic and responsive during such vulnerable moments? What role do clinical frameworks like attachment theory and transference play when working with powerful medicines like ketamine?

According to clinical psychologist Dr. Erika Czerwinski, relational attunement, psychoanalytic listening, and ceremony-based approaches can ground and enrich ketamine-assisted psychotherapy. Distinguishing dosages helps clinicians tailor interventions based on client needs and internal states. When clients begin regaining verbal awareness during ketamine sessions, gentle, well-timed reflections can surface unconscious material, validate emerging emotional experiences, and help anchor insights for integration. By attuning to transference patterns and unconscious processes, interpretations can deepen relational safety and accelerate healing.

In this episode of Living Medicine, Dr. Sandy Newes interviews Erika Czerwinski, PsyD, Founder, Director, and Facilitator of Eleos, about integrating relational depth into psychedelic-assisted psychotherapy. Dr. Czerwinski talks about working with clients experiencing personality disorders, the difference between psychedelic and psycholytic therapy sessions, and how ketamine compares to similar psychedelics in clinical usage.

Dissociative identity disorder (DID) is often misunderstood, stigmatized, or misdiagnosed, especially in high-functioning individuals who mask symptoms through adult-like coping strategies. Many live for decades without a clear diagnosis, struggling silently with memory gaps, emotional volatility, and identity confusion. How can modern therapeutic practices like psychedelic-assisted psychotherapy identify and support people navigating this complex condition?

Today’s guest struggled for years with DID that remained hidden behind a facade of accomplishments until various life stressors made symptoms unavoidable. Through intensive trauma therapy and psychedelic-assisted psychotherapy, they identified distinct parts within themself, recognized their trauma origins, and began the integration process. The guest emphasizes that psychedelics allow access to vivid trauma memories, the role of the therapist in creating safety and attunement during complex trauma work, and how gaining agency over their identities transformed their condition from a burden into a strength.

Join Dr. Signi Goldman in today’s episode of Living Medicine as she recounts an interview with an anonymous client about resolving DID through psychedelic-assisted psychotherapy. The guest talks about identifying and healing distinct internal identities, their early experience with DID symptoms, and how somatic touch can facilitate identity reconciliation.

Dr. Phil Wolfson, MD, is the Founder and CEO of the Ketamine Research Foundation, which advances ketamine’s use in therapeutic modalities. As a pioneering psychiatrist and psychotherapist, he is the author of The Ketamine Papers and Noe – A Father/Son Song of Love, Life, Illness and Death. Dr. Wolfson served as the Principal Investigator for a MAPS-sponsored Phase 2 clinical trial exploring MDMA-assisted psychotherapy for patients with anxiety from life-threatening illnesses.

As psychedelic-assisted therapies become more mainstream, ketamine treatments are increasingly medicalized, often lacking the integration, connection, and context that can unlock their true healing potential. How can clinicians ensure these therapies are transformative rather than transactional?

Psychedelic psychotherapist Dr. Phil Wolfson advises against separating ketamine from psychotherapy. Instead, he advocates for an integrative, human-centered approach that includes preparatory work, therapist presence, and post-session integration. When determining patient dosage, clinicians should focus on assessing the individual rather than adhering to rigid protocols. Dr. Wolfson also urges clinicians to cultivate compassion, deepen their therapeutic relationships, and consider the spiritual and emotional dimensions of healing, especially when working with trauma and grief.

In this episode of Living Medicine, Dr. Sandy Newes talks with Dr. Phil Wolfson, the Founder and CEO of the Ketamine Research Foundation, about the art and ethics of ketamine-assisted psychotherapy. Dr. Wolfson shares how his son’s illness led him to pursue psychedelic-assisted psychotherapy, consciousness and death in psychedelic experiences, and the contrast between IV clinics and integrative therapy models.